Student Author(s)

Yulian P. Ramirez; Jessica L. Weatherbee

Academic Program

Cancer Biology

UMMS Affiliation

Department of Biochemistry and Molecular Pharmacology

Publication Date


Document Type



Cancer Biology | Neoplasms | Therapeutics


Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.


angiogenesis, autophagy, imidazotetrazine, MGMT, DNA repair, temozolomide, cancer stem cells, UMCCTS funding

DOI of Published Version



Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506. doi: 10.3390/ph6121475. Link to article on publisher's website

Journal/Book/Conference Title

Pharmaceuticals (Basel)

Related Resources

Link to article in PubMed

PubMed ID